The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand
the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of
Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable
interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies
with two complementary and compelling technologies.
Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into
a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation.
The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means
to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We
are very pleased by the positive response we received from the investment community, which we want
to thank for the interest it has shown in Symetis. However, as of today, the company is taking another
path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional
cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to
be better treated for valvular heart disease globally. Moving forward, this means an exciting development
path for the Symetis team.”
Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since
2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition
of Symetis’ research and development track record in addressing patients’ needs with innovative
structural heart technologies, the company’s manufacturing expertise and its strong relationships with
doctors and healthcare professionals. We are excited about the strong potential of our combined
strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”
Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017
by Symetis on Euronext Paris, very well received by the investment community and which was originally
expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston
Scientific is projected to close during the second quarter of 2017, subject to customary closing
conditions.
Add Comment